Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: you miss a big point

"And as to Leckrone, it seems most folks believe he is no longer in the driver's seat on the issuance of PRs for PTSC. I certainly hope so, but even if he is, I still can't see a logical reason for withholding a PR on the NDCA Markman ruling."

There is one scenario which I hope isn't 'behind the curtains waiting to ambush us."

That is the scenario where an individual or consortium seeks to hold down PTSC's stock price while the said individual or consortium builds cash reserves to take the company private at a bargain rate so that said individual or consortium alone is able to take advantage of MMP revenues after such a change in control.

Share
New Message
Please login to post a reply